Good news flowed in at Gilead Sciences (GILD) with the FDA approving the company’s Harvoni for treating patients affected with chronic hepatitis C virus (HCV) genotype 1 infection. Harvoni is a once-daily combination treatment of Gilead’s highly successful HCV drug Sovaldi (sofosbuvir 400 mg) and ledipasvir (a NS5A inhibitor 90 mg). Following the FDA approval,…
For those willing to endure the inevitable price roller coaster, there’s tremendous opportunity in hyper-growth biotech stocks. But you have to pick the best stocks if you’re going to generate market-beating returns. So we have considered a simple question: “What is the best biotech stock for your portfolio?” Read below for the major picks. If…
Little-known medical equipment and biotech companies jumped on Wall Street on Monday, following news that a nurse had become the first person to contract the deadly Ebola virus in the United States. Shares of biotechnology company Ibio Inc , hazmat suits maker Lakeland Industries Inc , and face mask maker Alpha Pro Tech Ltd were…
While the broad-based SPDR S&P Biotech ETF has galloped higher by 20% year-to-date, a number of biotech stocks are wallowing near their 52-week lows. Could there be bargains to be had among this sea of red? With that in mind we three biotech stocks which have a good chance to turn things around; and here’s…
Last week, companies like Sunesis Pharmaceuticals, Inc (SNSS) and Chimerix, Inc (CMRX) were in the news due to pipeline updates. While Sunesis’ shares slumped on disappointing data, Chimerix made news related to the Ebola virus. Meanwhile, Regeneron’s (REGN) Eylea continues to gain approval for new indications. Sunesis’ shares tanked 78% on news that a pivotal…
Last week, Incyte Corporation (INCY) received a milestone payment of $60 million from Novartis (NVS) pertaining to the reimbursement of Jakavi in Europe. The drug has been approved by the European Commission to treat adults suffering from primary myelofibrosis (MF), post-polycythemia vera MF or post-essential thrombocythemia MF. It is a common practice of small pharma…
